All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Negma
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Agreement February 11, 2021
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Negma Group LTD
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Financing December 22, 2020
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Negma Group
Deal Size: $11.7 million Upfront Cash: Undisclosed
Deal Type: Financing November 05, 2020
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Janssen Ortho LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2020
Details:
The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
